Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An i3+3 Phase I Dose-per-Fraction Escalation Trial for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma

NCT05019976 is registered in ClinicalTrials.gov with University of Chicago as lead sponsor.

NCT NCT05019976
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05019976 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An i3+3 Phase I Dose-per-Fraction Escalation Trial for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma
Lead sponsor
University of Chicago
Phase
Not applicable
Overall status
Active, not recruiting
Start date
September 30, 2021
Completion date
December 1, 2027
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hodgkin lymphoma, lymphoma, non-hodgkin lymphoma